. Author manuscript; available in PMC: 2023 Jun 1.

Published in final edited form as: Transplant Cell Ther. 2022 Mar 11;28(6):304.e1–304.e9. doi: 10.1016/j.jtct.2022.03.005

Table 2.

Infections after BCMA-CARTx in participants with relapsed/refractory multiple myeloma

	Total participants	Total events	Mild events	Moderate events	Severe events
Fungal	2 (6)	2 (9)	0	0	2 (9)
Bacterial	6 (19)	7 (30)	3 (13)	1 (4)	3 (13)
Viral	13 (41)	14 (61)	3 (13)	10 (44)	1 (4)
*Any infection*	17 (53)	23 (100)	6 (26)	11 (48)	6 (26)

Data are shown as number (%). Percentages for Total participants were computed among n=32 total participants. All other percentages were computed among 23 total events.